The cyclic nucleotide phosphodiesterase 4 (PDE4) regulates the hydrolysis ... However, none of the PDE4 inhibitors tested so far has reached the market, mainly owing to tolerability issues such ...

The introduction of inhibitors of the cyclic GMP phosphodiesterase (PDE) 5 into clinical urology is mainly the result of the characterization of the physiology of nonvascular and vascular penile ...

A new study reports that mirodenafil, a newly developed oral phosphodiesterase ... These improvements were noted after 4 weeks of treatment. The PDE5 inhibitor also resulted in a more marked ...

Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...

Unlike other phosphodiesterase-4 inhibitors on the market, PALI-2108 is a new chemical entity and is being administered to humans for the first time. To gain insights into the therapy’s effects ...

Data presented at the 2025 Crohn's and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...